Navigation Links
Vasogen Announces First Quarter 2008 Results
Date:4/3/2008

rnal of Neuroscience (Vol 27, pp.294-

300, 2008).

- The results from the phase III ACCLAIM trial of our Celacade System

in patients with chronic heart failure were published in the

January 19th issue of The Lancet (Lancet 2008; 371: 228-36), a world-

leading medical journal. As we previously reported, while the trial

did not meet its primary endpoint, a key finding from the ACCLAIM

trial was a 39% reduction in the risk of death or cardiovascular

hospitalizations for a large pre-specified subgroup of patients with

NYHA Class II heart failure who received Celacade therapy, compared

to patients receiving placebo.

- On March 14, 2008, we had a teleconference with the FDA to discuss

and clarify the recent comments from the agency regarding the use of

a Bayesian approach for ACCLAIM II, a clinical trial which is being

planned to support an application for U.S. market approval of the

Celacade System for the treatment of patients with New York Heart

Association ("NYHA") Class II heart failure. The teleconference with

the FDA follows our announcement on March 3rd, stating that the FDA

disagrees with the use of a Bayesian approach for the planned ACCLAIM

II study. This is contrary to the FDA's original communication to us

recommending a Bayesian study design. We have prepared and submitted

a written response to the FDA's comments with respect to the use of a

Bayesian approach in ACCLAIM II.

- Grupo Ferrer Internacional, S.A. ("Ferrer"), our European marketing

partner, has the right to market Celacade for the treatment of

chronic heart failure in certain countries of the European Union

("E.U.") and Latin America. Celacade has already received E.U.

regulatory approval as a medical device under the CE Mark, which


'/>"/>
SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. Vasogen Provides Update on ACCLAIM II Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... pleased to announce that its wholly owned subsidiary, Portage ... PPL-003, to an Investigational New Drug (IND) application for ... PPL recently completed a study in a rat model ... highly significant efficacy and a more rapid onset of ...
(Date:8/31/2015)... and SHANGHAI , ... privately-held biopharmaceutical company developing next-generation antibiotics, today announced ... clinical study for its lead drug candidate MRX-I. ... treat drug-resistant bacteria such as MRSA and VRE, ... better tolerated therapeutic option than currently available oxazolidinone ...
(Date:8/31/2015)... Trimb Healthcare AB ("Trimb") today announced that ... BV ("YouMedical"), a Dutch OTC company with operations in ... approximately EUR 16 million, with solid growth and leading ... is to build a leading international OTC company, and ... YouMedical gives us a stronger North European OTC platform, ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment ... is the first commercially available new FDA approved system in the last 14 years, ... 92%, the high Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction rate ...
Breaking Biology Technology:Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 3MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3
... 2012   Spherix Incorporated (NASDAQ: SPEX ... diabetes, metabolic syndrome and atherosclerosis, and provider of technical ... pharmaceutical companies, today announced that it has entered into ... its common stock and warrants to purchase shares of ...
... Cambrex Corporation (NYSE: CBM ) announced ... on Monday, February 6, 2012 after the market closes. ... call to discuss the fourth quarter 2011 financial results.  ... Tuesday, February 7, 2012 at 8:30 a.m. Eastern Time ...
... strength of spider silk, the robust nature of the ... tears and winds that exceed hurricane strength. Now, ... with complex computer simulations has shown that web durability ... the overall web design compensates for damage and the ...
Cached Biology Technology:Spherix Announces Registered Direct Offering of $1.15 Million 2Spherix Announces Registered Direct Offering of $1.15 Million 3A spider web's strength lies in more than its silk 2A spider web's strength lies in more than its silk 3A spider web's strength lies in more than its silk 4
(Date:8/20/2015)... , Aug. 20, 2015 The ... consumers that are active and healthy. However, wearable ... the hospital environment to help improve diagnostic capabilities ... video from the Wearable Technologies Conference 2015 ... new applications for wearables in healthcare.    ...
(Date:8/18/2015)... , Aug. 17, 2015 Research ... addition of the "Global Biometric Authentication & ... - Estimation & Forecast, 2015-2020" report to ... authentication and identification systems market is expected to ... 2015 to 2020 and generate over $25 billion ...
(Date:8/12/2015)... , Aug. 12, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that four of its ... solution, have officially been named FIDO Certified™ by ... of the certification, Synaptics, Natural ID™ fingerprint solutions ... Authentication Framework (UAF) standard and are interoperable among ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
... 26 The Peter and Patricia Gruber Foundation International Prize ... with an event to be held at Rockefeller University in ... and Neuroscience Prize recipients will be announced live at the ... Brain, and Society." The discussion will feature a panel ...
... at the way that dolphins, whales and porpoises scythe ... maximum aquatic agility. However, no one had ever analysed ... lift that they generate, the drag that they experience ... from Duke University teamed up with Mark Murray from ...
... investigators in the Vanderbilt Center for Structural Biology have ... structure of the largest membrane-spanning protein to date. , ... pictures" of small proteins, large proteins and particularly ... been reluctant to smile for the camera. , In ...
Cached Biology News:NYC science symposium marks Gruber Prize program 10th anniversary 2Dolphins get a lift from delta wing technology 2Structural biology scores with protein snapshot 2Structural biology scores with protein snapshot 3
... , CapSure HS and CapSure Macro LCM ... of populations of pure cells from tissue ... Microdissection., Ensure the Integrity of Microdissected ... CapSure LCM Caps have a patented transfer ...
Opticon continuous fluorescence detector; includes optical base, analysis software, computer and monitor (this is an accessory for the DNA Engine thermal cyclers which must be ordered seperately)...
... on one plate. The new ArraySlide 96 ... (7mm x 7mm) individual printing surfaces for ... analysis studies. Unlike other systems, this device ... presence of contaminating adhesives. The chamber itself ...
... chambers for sealing hybridization reactions on slides. The ... on a glass slide. Reaction solution is added ... are then sealed with plastic sealing dots. Dots ... of reaction fluid. These chambers enclose a 20 ...
Biology Products: